Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00423644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Completed Primary completion date changed from estimate of Dec 2013 to Dec 21, 2007 · Study completion date changed from estimate of Dec 2013 to Dec 21, 2008v6 Show 2 more changesShow less
    • Primary completion date changed from estimate of Dec 2013 to Dec 21, 2007
    • Study completion date changed from estimate of Dec 2013 to Dec 21, 2008
  2. Primary and study completion dates: Jun 2013 to Dec 2013v5
  3. Primary and study completion dates: Mar 2008 to Jun 2013 Trial status: Completed to Active, Not Recruitingv4 Show 1 more changeShow less
    • Trial status: Completed to Active, Not Recruiting
  4. Trial status: Active, Not Recruiting to Completed Enrollment target: estimated 40 to confirmed 17 · Primary and study completion dates changed from estimate of May 2008 to Mar 2008v3 Show 2 more changesShow less
    • Enrollment target: estimated 40 to confirmed 17
    • Primary and study completion dates changed from estimate of May 2008 to Mar 2008
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting Study sites: 2 to 8 · Primary and study completion dates: May 2008 · Start date: Jan 2007 · 3 morev2 Show 6 more changesShow less
    • Study sites: 2 to 8
    • Primary and study completion dates: May 2008
    • Start date: Jan 2007
    • Interventions: ZIO-101 (Drug) to Darinaparson (Drug)
    • Eligibility criteria expanded, about 323 words
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Trial Details
NCT Number NCT00423644
Lead Sponsor Alaunos Therapeutics
Conditions Multiple Myeloma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov